Tina Verschuere

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

Abhishek D. Garg, Lien Vandenberk, Carolien Koks et al. · Science Translational Medicine · 2016 · 267 citations

Medicine, Immunology, Oncology +14

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

Hilko Ardon, Stefaan W. Van Gool, Tina Verschuere et al. · Cancer Immunology Immunotherapy · 2012 · 160 citations · Full text

Medicine, Immunology, Oncology +16

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Martin J. van den Bent, Martin Klein, Marion Smits et al. · The Lancet Oncology · 2018 · 130 citations · Full text

Medicine, Oncology, Pharmacology +16

Glioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity

Tina Verschuere, Jaan Toelen, Wim Maes et al. · International Journal of Cancer · 2013 · 86 citations · Full text

Medicine, Immunology, Oncology +17

Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth

Thomas Mathivet, Claire Bouleti, Matthias Van Woensel et al. · EMBO Molecular Medicine · 2017 · 74 citations · Full text

Medicine, Cancer Biology, Oncology +17